Overview of Current Treatment Strategies in Prostate Cancer

European Urology, Supplements

Volumn 3, Issue 1, 2004, Pages 2-7

  Bono, Aldo V ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Advanced disease; Hormone therapy; Localised disease; Locally advanced disease

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; ENDOTHELIN RECEPTOR ANTAGONIST; ESTROGEN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; KETOCONAZOLE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SULINDAC; VITAMIN D;

ADVANCED CANCER; BIOCHEMISTRY; BONE METASTASIS; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; GENE THERAPY; GYNECOMASTIA; HORMONE RESISTANCE; HUMAN; INCIDENTAL FINDING; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 1042266443     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.12.002     Document Type: Conference Paper

References (31)

1. American Society for Therapeutic Radiology and Oncology. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. http://www.astro.org .
2. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341(24):1999;1781-1788.
3. Zincke H., Lau W., Bergstralh E., Blute M.L. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J. Urol. 166(6):2001;2208-2215.
4. See WA, Wirth M, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DMA, Delaere KPJ, Vaage S, Tammela TLJ, Lukkarinen O, Persson BO, Carroll K, Kolvenbag GJCM on behalf of the Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168(2):429-35.
5. Health Canada. Dear Healthcare Professional Letter, August 18, 2003.
6. Schroeder FH. Early versus delayed therapy in N+ prostate cancer. EAU Annual Congress, Madrid, March 2003.
7. Walsh P.C. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J. Urol. 158(4):1997;1623-1624.
8. Valicenti R.K., Gomella L.G., Perez C.A. Radiation therapy after radical prostatectomy: A review of the issues and options. Semin. Radiat. Oncol. 13(2):2003;130-140.
9. Lennernas B., Edgren M., Haggman M., Norlen B.J., Nilsson S. Postoperative radiotherapy after prostatectomy - a review. Scand. J. Urol. Nephrol. 37(1):2003;10-15.
10. Soloway M.S., Sharifi R., Wajsman Z., McLeod D., Wood D.P. Jr., Puras-Baez A. Randomised prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 154(2 Pt 1):1995;424-428.
11. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP, Puras-Baez A, Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167(1):112-6.
12. Bono AV, Pagano F, Montironi R, Zattoni F, Manganelli A, Selvaggi FP, Comeri G, Fiaccavento G, Guazzieri S, Selli C, Lembo A, Cosciani-Cunico S, Potenzoni D, Muto G, Diamanti L, Santinelli A, Mazzucchelli R, Prayer-Galletti T, Italian PROSIT Study Group. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 2001;57(1):117-21.
13. Noguchi M., Noda S., Nakashima O., Kojiro M. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer. Oncol. Rep. 9(5):2002;1075-1080.
14. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group. Randomised comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166(2):500-6 [Discussion 506-7].
15. Lorente J.A., Arango O., Bielsa O., Cortadellas R., Lloreta-Trull J., Gelabert-Mas A. A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer. Eur Urol. 43(2):2003;119-123.
16. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G.et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337(5):1997;295-300.
17. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B.et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J. Clin. Oncol. 15(3):1997;1013-1021.
18. Merrick G.S., Butler W.M., Galbreath R.W., Lief J.H., Adamovich E. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? Br. J. Urol. Int. 91(1):2003;23-29.
19. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, Zattoni F, EAU Working Group on Oncological Urology. EAU guidelines on prostate cancer. Eur Urol 2001;40(2):97-101.
20. Boccon-Gibod L., Bertaccini A., Bono A.V., Dev Sarmah B., Holtl W., Mottet N.et al. Management of locally advanced prostate cancer: a European consensus. Int. J. Clin. Pract. 57(3):2003;187-194.
21. Eisenberger M.A., Blumenstein B.A., Crawford E.D., Miller G., McLeod D.G., Loehrer P.J.et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339(15):1998;1036-1042.
22. Denis L., Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 72(Suppl. 12):1993;3888-3895.
23. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355(9214):1491-8.
24. Mottet N., Costa P., Navratil H. Intermittent versus continuous hormone deprivation in metastatic prostate cancer: preliminary data from an ongoing European study. Prostate Cancer Prostatic Dis. 2(S2):1999;S2-S4.
25. Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K, Scandinavian Prostatic Cancer Group (SPCG). A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002;42(3):204-11.
26. Tyrrell C.J., Kaisary A.V., Iversen P., Anderson J.B., Baert L., Tammela T.et al. A randomised comparison of 'Casodex' (bicalutamide) 150. mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur. Urol. 33(5):1998;447-456.
27. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E, Scandinavian Prostatic Cancer Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36(6):405-13.
28. Harris K.A., Rees D.M. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. 61(15):2001;2177-2192.
29. Sternberg C.N. Highlights of contemporary issues in the medical management of prostate cancer. Crit. Rev. Oncol. Hematol. 43(2):2002;105-121.
30. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB, Abarelix Study Group. A phase 3, multicenter, open label, randomised study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167(4):1670-4.
31. Beer T.M., Garzotto M., Eilers K.M., Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J. Urol. 169(5):2003;1745-1746.